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Introduction
Acute kidney injury (AKI), chronic kidney disease, and 
the evaluation of numerous exogenous and endogenous 
measures of kidney function and injury continue to be 
the focus of much research in diﬀ  erent  patient 
populations. Th   e key reason behind this eﬀ  ort is the well 
described independent association that small changes in 
kidney function are strongly linked with increased 
mortality, extending to those with chronic liver disease.
Th   e accurate assessment of kidney function and injury 
is currently aﬀ   ected by the reliance on the measured 
concentration of serum creatinine, which is signiﬁ  cantly 
aﬀ  ected by the degree of cirrhosis, hyperbilirubinemia, 
and the nutritional state of the patient. Improved under-
standing of the pathophysiology of kidney injury and 
development of more accurate measures of kidney 
function and injury are necessary to evoke a positive shift 
in kidney injury diagnosis, treatment, and outcomes. 
Furthermore, the number of patients with chronic liver 
disease and chronic kidney disease continues to rise, due 
to the large numbers of individuals worldwide aﬀ  ected by 
viral hepatitides, obesity, hypertension, and diabetes. 
Consequently, preventative health care messages must be 
louder and further reaching in order to reverse this trend.
Co-existing liver and kidney disease
Chronic liver disease and primary liver cancer account 
for 1 in 40 (2.5%) deaths worldwide, with hepatitis B the 
commonest cause in the developing world, followed by 
alcoholic liver disease and hepatitis C in the Western 
world [1]. Non-alcoholic steato-hepatitis and non-
alcoholic fatty liver disease are increasing causes of 
chronic liver disease in the general population of Western 
countries with prevalence rates of 1–5% and 10–24%, 
respectively [2]. Th  is observation is related to the 
increasing incidence of obesity in the Western population 
and the associated metabolic syndrome, consisting of 
atherosclerotic coronary vascular disease, hypertension, 
hyperlipidemia, diabetes, and chronic kidney disease. 
Metabolic syndrome and non-alcoholic steato-hepatitis/
non-alcoholic fatty liver disease are linked by the key 
feature of insulin resistance. Although initially considered 
to be a benign disease, non-alcoholic fatty liver disease 
seems to represent a spectrum of disease with benign 
hepatic steatosis at one end and steatotic hepatitis at the 
other. Approximately 30–50% of individuals with steato-
hepatitis will develop ﬁ  brosis, 15% cirrhosis, and 3% liver 
failure [2]. Importantly, non-alcoholic fatty liver disease 
probably accounts for a large proportion of patients 
diagnosed with cryptogenic cirrhosis and at least 13% of 
cases of hepatocellular carcinoma [3, 4].
Obesity and metabolic syndrome are also strongly 
associated with the development of hypertension and 
diabetes, which aﬀ  ect 70% of the patient population with 
end-stage renal disease in the USA [5]. Th   ere is increasing 
evidence that obesity itself is an independent risk factor, 
albeit small, for the progression of chronic kidney 
disease. Some work has highlighted the association of 
low-birth weight and reduced nephron mass with an 
increased risk of obesity and the phenomenon of chronic 
kidney disease later in life [6]. A small proportion of 
obese patients will develop obesity-related glomerulo-
sclerosis, a focal segmental glomerulonephropathy asso-
ciated with proteinuria and progression to end-stage 
renal disease. Despite numerous obesity-related factors, 
the overall individual risk for the development of chronic 
kidney disease in the absence of diabetes and hyper-
tension is low; nevertheless, obesity is likely to contribute 
increasingly to the burden of chronic disease and end-
stage renal disease in the future.
Hepatitis C has long been associated with several 
glomerulopathies, most notably cryoglobulin- and non-
cryoglobulin-associated membranoproliferative glomeru-
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around 50% [7], although extrarenal manifestations are 
often absent in themajority of these patients. Viral RNA, 
proteins and particles have been inconsistently isolated 
from kidney biopsy specimens, making it diﬃ   cult  to 
establish whether hepatitis C is causative in other forms 
of glomerulopathy [7]. In seropositive hepatitis C 
populations, hepatitis C infection has been reported to 
be associated with focal segmental glomerulosclerosis, 
membranous nephropathy with or without nephrotic 
range proteinuria, IgA nephropathy, and proliferative 
glomerulonephritidies [7].
Hepatitis C has also been associated with an increased 
risk of albuminuria, progression of diabetic nephropathy, 
and progression of chronic kidney disease to endstage 
renal disease [7]. Th   e worldwide prevalence of hepatitis C 
among patients on hemodialysis is high, ranging from 4–
60% [8]. Th  is rate is on the decline, due to stricter 
adherence to universal infection control measures, with 
or without isolation, which have been implemented to a 
greater extent in the USA and in European countries. 
Risk factors for infection include the length of time of 
hemodialysis, the number of blood transfusions for renal 
anemia, and nosocomial transmission [8]. Th  ese  patients 
often develop signiﬁ   cant chronic liver disease, which 
adds an additional mortality burden while on hemo-
dialysis. Th   e presence of hepatitis C infection also has a 
negative eﬀ  ect on patient and renal survival following 
kidney transplantation [9].
Hepatitis B virus (HBV) is also associated with renal 
disease, but it is mostly encountered in children from 
endemic areas. Th  e incidence of HBV-associated renal 
disease in Europe is low due to the lower prevalence of 
chronic HBV infection. HBV is associated with a number 
of renal diseases, including polyarteritis nodosa, mem-
branous and membranoproliferative glomerulonephritis. 
Most patients have a history of active HBV but are 
asymptomatic with positive surface antigen and core 
antibody; in those with membranous nephropathy, e 
antigen is positive. Th   e pathogenic role of HBV has been 
demonstrated by the presence of antigen-antibody com-
plexes in kidney biopsy specimens and in particular 
deposition of HBV e antigen in membranous glomerulo-
nephritis [9, 10].
Autosomal-dominant polycystic kidney disease is 
associated with polycystic liver disease in up to 75–90% 
of cases [11]. Th   ere are a number of risk factors for liver 
involvement, including female gender, age, and degree of 
renal dysfunction [11]. A distinct form of autosomal 
dominant isolated liver cystic disease was recognized in 
the mid-1980s. Most patients are asymptomatic, but 
when symptoms do occur, they are often related to cyst 
size and number. Symptoms include abdominal pain, 
nausea, early satiety, breathlessness, ascites, and biliary 
obstruction; all can precipitate to result in a signiﬁ  cantly 
malnourished state related to gastric compression. Th  e 
medical complications seen with autosomal-dominant 
polycystic kidney disease including intracranial aneur-
ysms, and valvular heart lesion are also encountered in 
those with cystic liver disease. Th  erapies involve cyst 
rupture or sclerosis and liver transplantation if symptoms 
persist [11].
Familial amyloidosis polyneuropathy is an autosomal 
dominant disease caused by a point mutation in the gene 
coding for transthyretin, also called pre-albumin. Th  e 
amino acid, valine, is replaced by methionine. Th  e 
mutated protein produced by the liver forms a beta-
pleated sheet structure, which accumulates in tissues, 
particularly nerves and the kidney, resulting in amyloid 
deposition. Familial amyloidosis polyneuropathy appears 
in the second decade of life leading to death within 8–
13 years. Orthotopic liver transplantation (OLT) represents 
the best form of treatment, when performed early in the 
course of the disease, by halting the progression of the 
peripheral neuropathy and chronic kidney disease. Th  e 
kidneys are frequently aﬀ  ected and this is recognized by 
proteinuria and declining kidney function. OLT reduces 
serum pre-albumin levels but the amount deposited in 
the kidney remains the same post transplantation. OLT 
should not be contemplated for patients with severe 
proteinuria or advanced chronic kidney disease [12].
Serum creatinine concentration for the assessment 
of kidney function in chronic liver disease
Kidney function is evaluated by assessing the glomerular 
ﬁ   ltration rate (GFR), which can be determined by 
measuring the volume of plasma that can be completely 
cleared of a given substance over a deﬁ  ned unit of time. 
Th   e ideal marker for GFR determination is often quoted 
as having the following characteristics: Appears con-
stantly in the plasma, can be freely ﬁ   ltered at the 
glomerulus, and does not undergo tubular reabsorption, 
secretion or extra renal elimination [13]. For many years 
now, the assessment of GFR has relied on the measure-
ment of the concentration of serum creatinine, which is 
associated with many problems. Creatinine is a product 
of the metabolism of creatine, which is produced in the 
liver from three amino acids, methionine, arginine, and 
glycine, and stored in muscle to be used as a source of 
energy once phosporylated. Creatinine does not appear 
in the plasma at a constant rate; it is secreted in the 
tubule and can undergo extrarenal elimination, thought 
to involve creatinase in the gut. Serum creatinine 
concentration displays an exponential relationship with 
GFR, rendering it speciﬁ  c, but not a sensitive measure of 
GFR. Th  e creatinine pool is aﬀ   ected by gender, age, 
ethnicity, nutritional state, protein intake and importantly 
liver disease [14].
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creatinine pool is due to a 50% decrease in hepatic 
production of creatine; increases in the volume of distri-
bution due to the accumulation of extracellular ﬂ  uid, 
edema, and ascites; malnutrition and loss of muscle mass, 
which is related to repeated episodes of sepsis and large 
volume ascites aﬀ  ecting satiety [15]. Ultimately, patients 
with chronic liver disease have a signiﬁ  cantly  lower 
baseline serum creatinine concentration than the general 
population (35–75 μmol/l).
Analytical methods for measuring the serum creatinine 
concentration have been associated with problems, 
particularly related to interference from chromatogens, 
like unconjugated and conjugated bilirubin. Th  e degree 
of error can be up to 57% [16], but modern auto-analyzers 
using the endpoint Jaﬀ   e method have overcome such 
interference. Nevertheless, interpreting serum creatinine 
results in the context of hyperbilirubinemia still requires 
a degree of caution despite these adjustments. In parti-
cular, patients with chronic liver disease display smaller 
and delayed (up to 48–72 hours) changes in serum 
creatinine for a given change in GFR, thus impairing the 
recognition and underestimating the degree of change in 
GFR [17, 18].
Acute kidney injury network criteria for staging 
acute kidney injury
In 2005 the Acute Kidney Injury Network (AKIN) was 
formed, comprising a group of experts in nephrology and 
critical care who sought to revise the Acute Dialysis 
Quality Initiative (ADQI) group’s original work from the 
previous year, which resulted in the development of the 
RIFLE (Risk, Injury, Failure, Loss, End-stage renal 
disease) criteria. A unifying term for acute renal failure, 
acute kidney injury (AKI), which encompassed all causes 
of acute renal failure, was established along with speciﬁ  c 
deﬁ  ning criteria and a classiﬁ  cation based on severity of 
disease (Table 1) [19]. Patients are assigned to the worse 
category within the RIFLE criteria, deﬁ  ned by changes in 
serum creatinine concentration or GFR from baseline or 
urine output per unit body weight per hour over a 
deﬁ   ned period of time. Th  e AKIN reﬁ   ned the RIFLE 
criteria to reﬂ   ect data demonstrating the ﬁ  nding  that 
small changes in serum creatinine had a signiﬁ  cant 
impact on patient mortality [19]. Th   e ‘Risk’ category for 
AKI was broadened to include changes in serum 
creatinine up to 26.4 umol/l within a 48 hour time frame.
Th  e stages of AKI in this revised classiﬁ  cation were 
numbered 1, 2, and 3 rather than being named ‘Risk’, 
‘Injury’ and ‘Failure’. Th  e category of ‘Failure’ becomes 
Stage 3 AKI and incorporates anyone commenced on 
renal replacement therapy regardless of serum creatinine 
or rate of urine output (Table 1). More subtle changes 
include the exclusion of urinary tract obstruction and 
easily reversible causes of transient change in serum 
creatinine or urine output, such as volume depletion. 
Importantly, the inappropriate use of estimated GFR in 
the acute setting was addressed by removing the GFR 
criteria altogether.
Despite these revisions, there remain problems with 
both staging systems and these have been the focus of 
much discussion in the literature. Direct comparison of 
the two staging systems has been performed and, as 
expected, AKI is more sensitive than RIFLE, but this 
diﬀ   erence only aﬀ   ects around 1% of patients [20]. Th  e 
choice of baseline creatinine for studies has been 
highlighted to be of critical importance, markedly aﬀ  ecting 
the incidence of AKI. Several retrospective studies have 
calculated the baseline serum creatinine by manipulating 
the Modiﬁ   cation of Diet in Renal Disease (MDRD) 
equation for estimating GFR assuming that patients had an 
estimated GFR of 75–100 ml/min/1.73 m2 [21].
It is also evident that slow but persistent changes in 
serum creatinine over a longer time course than 48 hours 
can be missed and sometimes impossible to classify. 
Urine output too is associated with a number of 
confounding factors, in particular diuretic use, which 
aﬀ  ects interpretation. Extracorporeal therapies like con-
tinuous veno-venous hemoﬁ  ltration (CVVH), a form of 
renal replacement therapy used in the critically ill, are 
often initiated for non-renal reasons, for example, hyper-
lactatemia or hyperammonemia which are frequently 
encountered in acute liver failure. More prospective 
studies with more attention to detail are required to 
improve the AKI criteria, in particular ensuring that 
baseline creatinine is measured and not estimated, and 
providing greater description of the indications for and 
timing of renal replacement therapy [21].
Table 1. Acute Kidney Injury Network (AKIN) acute kidney injury staging criteria [19]
  Serum creatinine (μmol/l)  Urine output (ml/kg/h)
Stage 1  > 26.4 μmol/l   < 0.5 for > 6 hours
  > 150–200% change from baseline
Stage 2  > 200–300% change from baseline  < 0.5 for > 12 hours
Stage 3  > 300% change from baseline   < 0.3 for 24 hours or anuria for 12 hour
 OR 
  > 44 μmol/l change from 354 μmol/l
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phenomenon of the lower baseline serum creatinine seen 
in patients with chronic liver disease. Th   e broadening of 
stage 1 is beneﬁ  cial in the setting of chronic liver disease, 
because we know that changes in serum creatinine will 
be smaller and delayed. Urine output, although riddled 
with numerous confounders, not least diuretic therapy 
and the diﬃ   culties of the un-catheterized patient, can 
still yield important information if measured accurately 
on the ward in conjunction with daily weight assessment 
to provide an assessment of overall ﬂ  uid balance. Diuretic 
therapy response varies in patients with decompensated 
chronic liver disease and has a signiﬁ   cant impact on 
survival outcomes; those that are less responsive tend to 
experience complications of hyponatremia and AKI with 
greater frequency [22].
Acute kidney injury pathogenesis
AKI is more than just an isolated ischemic injury. Th  e 
ischemic insult stimulates an inﬂ  ammatory  response 
with increased expression of adhesion molecules 
attracting leukocytes. Intra-luminal debris from tubular 
cells damaged by ischemia impairs reabsorption of 
sodium, which polymerizes Tamm-Horsfall proteins 
form  ing a gellike substance that occludes the tubule 
causing increased backpressure and leaking. Endothelial 
injury aﬀ  ects tonicity of the aﬀ  erent arteriole, activates 
the clotting cascade and releases endothelin which causes 
further vasoconstriction thus compromising the micro-
circulation. An injurious reperfusion period can then 
follow, due to the depletion of ATP, which releases 
proteases with oxidative substances that further damage 
the cytoskeleton of the tubules. Th  is  pathogenesis 
perhaps explains the unresponsive nature of this 
condition when identiﬁ  ed late in its clinical course [23].
Patients with chronic liver disease are more 
susceptible to acute kidney injury
Advanced chronic liver disease is responsible for a 
signiﬁ  cant number of physiological changes that aﬀ  ect 
the circulation and kidney perfusion. Cirrhosis results in 
the accumulation of vasodilatory mediators, in particular 
nitric oxide (NO), which speciﬁ   cally vasodilates the 
splanchnic circulation reducing the eﬀ  ective circulating 
blood volume and mean arterial pressure. Hypoperfusion 
of the kidneys leads to a reduction in the sodium 
concentration of tubular ﬂ  uid reaching the distal tubule 
stimulating the macular densa, to release renin, thus 
activating the renin-angiotensin-aldosterone (RAA) axis. 
Glomerular ﬁ  ltration pressure is dependent on aﬀ  erent 
and eﬀ  erent vascular tone. Chronic disease states often 
seen in association with chronic liver disease, such as 
atherosclerotic vascular disease, hypertension and 
chronic kidney disease, aﬀ  ect the responsiveness of the 
aﬀ  erent arteriole, thus shifting the auto regulation curve 
to the right. Consequently, adjustments in vascular tone 
of the aﬀ  erent arteriole are smaller, reducing the ability to 
increase glomerular perfusion during episodes of hypo-
tension. Th  is, coupled with increased levels of angio-
tensin II, a product of RAA activation, causes vaso-
constriction of blood vessels, in particular the aﬀ  erent 
and eﬀ  erent arteriolar renal vessels. Aldosterone acts on 
the distal tubule increasing the retention of salt and 
water. Consequently, there is decreased renal perfusion 
coupled with avid retention of ﬂ   uid which increases 
abdominal ascites accumulation causing abdominal 
distension and elevation of the intra-abdominal pressure, 
which further compromises renal perfusion and propa-
gates the vicious cycle.
Furthermore, in advanced chronic liver disease, an 
intrinsic defect in cardiac performance during exercise 
has been demonstrated and termed cirrhotic cardiomyo-
pathy [24]. Th  is syndrome encompasses a number of 
myocardial and electrophysiological changes that occur 
in cirrhosis and lead to attenuated cardiac function, 
particularly when exposed to stressful events like sepsis. 
Th  e features of this condition include: A hyperdynamic 
myocardium with an increase in baseline cardiac output; 
attenuated systolic contraction and diastolic relaxation; 
electrophysiological abnormalities; and unresponsiveness 
to beta-adrenergic stimulation. Portal hypertension leads 
to shunting of blood away from the liver, thus reducing 
portal venous blood ﬂ  ow in the liver. Th   is is thought to 
aﬀ  ect sodium and water excretion by the kidney via the 
postulated hepatorenal reﬂ   ex mechanism whereby the 
release of adenosine is believed to act as a neuro-
transmitter stimulating sympathetic nerves supplying the 
renal vasculature causing vasoconstriction and oliguria. 
Th   ese mechanisms, attempting to maintain the eﬀ  ective 
circulating blood volume coupled with cirrhotic cardio-
myopathy and reduced venous return from raised intra-
abdominal pressure, render the circulation helpless in the 
pursuit of renal perfusion preservation.
Stress events like sepsis, gastrointestinal bleeding, and 
the use of diuretics, vasodilators or nephrotoxic drugs, 
which cause renal vasoconstriction, like non-steroidal 
anti-inﬂ  ammatory drugs and radiographic contrast agents, 
can tip this ﬁ  ne balance between circulatory performance 
and adequacy of renal perfusion resulting in renal ischemia 
and its associated multi-faceted sequelae. Subsequently, 
AKI ensues, unless timely interventions targeted at 
reversing these physiological changes are initiated.
Hepatorenal syndrome
Hepatorenal syndrome was ﬁ   rst described in 1939 in 
patients undergoing biliary surgery [25] and today it 
remains a clinical entity assigned speciﬁ  c  deﬁ  ning 
criteria. It is divided into two types based on speciﬁ  c 
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type 1 is a form of AKI, similar to that encountered in 
sepsis, which necessitates the exclusion of reversible 
factors, treatment of hypovolemia, nephrotoxic medica-
tions, and a period of resuscitation to assess response to 
diuretic withdrawal and volume expansion; hepatorenal 
syndrome type 2 is a form of chronic kidney disease 
related to diuretic resistant ascites and its management, 
which typically evolves over months, perhaps displaying 
features in common with the ischemic nephropathy 
encountered in severe cardiac failure.
Th  e classifying criteria for deﬁ  ning hepatorenal syn-
drome are under constant review and scrutiny, in a 
similar fashion to the AKI and chronic kidney disease 
classiﬁ  cations. Problems persist with all three classiﬁ  ca-
tions largely due to the reliance on serum creatinine 
concentration. As already discussed, serum creatinine 
performs poorly as a marker of kidney function in many 
diﬀ   erent cross-sectional patient populations, not least 
those with chronic liver disease. Th  e subgroup classiﬁ  -
cation of types 1 and 2 hepatorenal syndrome have 
surprisingly not yet embraced the AKI and chronic 
kidney disease staging criteria, respectively. Th  e 
deﬁ  nition of hepatorenal syndrome is centered on the use 
of an arbitrary level for serum creatinine concentration of 
130 μmol/l, which does not account for gender, ethnicity, 
age or for the lower baseline serum creatinine concen-
trations seen in patients with chronic liver disease. 
Conse  quently, patients with chronic liver disease will lose 
more than 50% of residual renal function before a 
diagnosis of hepatorenal syndrome can be entertained. 
Despite the ﬂ  aws associated with the AKI classiﬁ  cation, 
which are explained below, it seems to have some clear 
advantages, with at least the recognition that individual 
baseline creatinine concentration is a much better 
starting reference point.
Acute kidney injury and chronic liver disease
Th  e incidence of AKI in hospitalized patients with 
chronic liver disease is around 20% [26]. Th   ere are three 
main causes of AKI in chronic liver disease: Volume-
responsive pre-renal failure, volume unresponsive pre-
renal failure with tubular dysfunction and acute tubular 
necrosis (ATN), and hepatorenal syndrome type 1, with 
prevalence rates of 68%, 33%, and 25% respectively [27]. 
Of note, these three clinical scenarios should only be 
considered once acute kidney parenchymal disease and 
obstructive uropathy have been excluded. Th  is  exclusion 
can be achieved by performing an ultrasound of the 
kidneys, dipstick urine analysis assessing the presence of 
hematuria and proteinuria, and appropriate same day 
serological testing for antibodies against the glomerular 
basement membrane and for vasculitis if other clinical 
features suggest such diagnoses are possible. Additionally, 
the thorough evaluation and pursuit of occult sepsis is 
crucial with the early introduction of appropriate broad 
spectrum antibiotics often proving to be vital. Approxi-
mately 20% of patients with decompensated chronic liver 
disease will have spontaneous bacterial peritonitis [28]. 
Th   e diagnostic ascitic tap is an invaluable test to rule out 
this condition, which can be a precipitant of AKI in about 
30% of cases. Hypotension in patients with chronic liver 
disease should prompt meticulous assessment for 
gastrointestinal bleeding, with variceal hemorrhage an 
easily treatable cause. Again a detailed search for sepsis 
and thorough interrogation of the drug chart to stop 
medications that compromise blood pressure or could in 
anyway be nephrotoxic is always warranted. Established 
beneﬁ   cial treatments include ﬂ  uid  resusci  tation, 
vasopressor analog use, albumin infusions, and the 
omission of nephrotoxic drugs [29, 30].
Biomarkers of AKI
Traditional blood markers of kidney injury, such as 
serum creatinine, urea and urine markers, fractional 
excretion of sodium, and casts on microscopy, are 
insensitive and non-speciﬁ   c for the diagnosis of AKI. 
Novel kidney injury biomarkers in both serum and urine 
have been discovered using genomic and proteomic 
technology and they are demonstrating superiority in 
detecting kidney injury before changes in serum 
creatinine occur. Th  ese markers have been assessed 
primarily after a known speciﬁ  c insult in both adult and 
pediatric populations, such as cardiopulmonary bypass 
for cardiac surgery, kidney transplantation, contrast 
administration, or sepsis and other pathologies 
encountered in intensive care populations. Subsequently, 
numerous systematic reviews have been undertaken to 
assess the validity of these studies. Currently the 
literature supports the concept of a panel of biomarkers 
for detecting AKI, including two serum and three urine 
biomarkers: Serum neutrophil gelatinase lipocalin 
(sNGAL) and cystatin C, and urinary kidney injury 
molecule 1 (KIM-1), interleukin-18 (IL-18) and NGAL 
(uNGAL) [31].
Table 2 illustrates the major studies for each of these 
biomarkers in the setting of AKI with as many as 31 
studies demonstrating broadly similar outcomes [32–35]. 
However, it is diﬃ   cult to translate these studies to the 
wider patient population or indeed speciﬁ  cally to those 
with chronic liver disease. Many of the 31 studies 
excluded patients with chronic kidney disease, which 
aﬀ  ects 30% of patients admitted to intensive care and 
these patient have an increased risk of AKI [36]. Two 
large multicenter studies are underway evaluating these 
biomarkers and our research group at King’s College 
Hospital is evaluating the use of these biomarkers in 
patients with chronic liver disease. Some work has 
Slack et al. Critical Care 2010, 14:214 
http://ccforum.com/content/14/2/214
Page 5 of 10T
a
b
l
e
 
2
.
 
S
u
m
m
a
r
y
 
o
f
 
s
t
u
d
i
e
s
 
e
v
a
l
u
a
t
i
n
g
 
t
h
e
 
r
o
l
e
 
o
f
 
n
o
v
e
l
 
b
l
o
o
d
 
a
n
d
 
u
r
i
n
e
 
k
i
d
n
e
y
 
i
n
j
u
r
y
 
b
i
o
m
a
r
k
e
r
s
S
t
u
d
y
 
N
 
[
R
e
f
]
B
i
o
m
a
r
k
e
r
B
i
o
m
a
r
k
e
r
 
p
r
o
fi
 
l
e
P
r
e
c
i
p
i
t
a
n
t
s
 
a
n
d
 
C
o
n
f
o
u
n
d
e
r
s
C
l
i
n
i
c
a
l
 
s
e
t
t
i
n
g
C
u
t
-
o
ff
 
A
K
I
 
d
e
fi
 
n
i
t
i
o
n
S
e
n
s
i
t
i
v
i
t
y
S
p
e
c
i
fi
 
c
i
t
y
A
U
C
M
i
s
h
r
a
 
e
t
 
a
l
.
 
N
 
=
 
7
1
 
[
3
2
]
S
e
r
u
m
 
N
G
A
L
2
5
 
k
D
a
 
p
r
o
t
e
i
n
 
b
o
u
n
d
 
t
o
 
g
e
l
a
t
i
n
a
s
e
 
f
r
o
m
 
n
e
u
t
r
o
p
h
i
l
s
.
 
 
E
x
p
r
e
s
s
e
d
 
i
n
 
l
o
w
 
l
e
v
e
l
s
 
i
n
 
n
o
r
m
a
l
 
t
i
s
s
u
e
s
,
 
k
i
d
n
e
y
,
 
l
u
n
g
 
a
n
d
 
c
o
l
o
n
.
 
I
n
c
r
e
a
s
e
d
 
l
e
v
e
l
 
w
i
t
h
 
d
a
m
a
g
e
 
t
o
 
e
p
i
t
h
e
l
i
a
l
 
c
e
l
l
s
.
S
e
p
s
i
s
I
s
c
h
e
m
i
a
N
e
p
h
r
o
t
o
x
i
n
s
C
K
D
U
T
I
 
a
n
d
 
s
y
s
t
e
m
i
c
 
s
e
p
s
i
s
C
a
r
d
i
a
c
 
s
u
r
g
e
r
y
C
h
i
l
d
r
e
n
2
 
h
 
p
o
s
t
 
c
a
r
d
i
a
c
 
s
u
r
g
e
r
y
5
0
 
μ
g
/
l
>
 
5
0
 
%
 
r
i
s
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
s
e
r
u
m
 
c
r
e
a
t
i
n
i
n
e
0
.
7
0
.
9
4
N
R
H
e
r
g
e
t
-
R
o
s
e
n
t
h
a
l
 
e
t
 
a
l
.
 
N
 
=
 
8
5
 
[
3
3
]
S
e
r
u
m
 
c
y
s
t
a
t
i
n
 
C
1
3
 
K
D
a
 
p
r
o
t
e
i
n
 
f
r
o
m
 
c
y
s
t
e
i
n
e
 
p
r
o
t
e
a
s
e
 
i
n
h
i
b
i
t
o
r
 
f
a
m
i
l
y
 
p
r
o
d
u
c
e
d
 
b
y
 
a
l
l
 
n
u
c
l
e
a
t
e
d
 
c
e
l
l
s
.
 
M
e
a
s
u
r
e
 
o
f
 
G
F
R
 
a
s
 
f
r
e
e
l
y
 
fi
 
l
t
e
r
e
d
 
a
t
 
p
r
o
x
i
m
a
l
 
t
u
b
u
l
e
.
U
n
a
ff
 
e
c
t
e
d
 
b
y
 
g
e
n
d
e
r
,
 
a
g
e
,
 
e
t
h
n
i
c
i
t
y
 
o
r
 
m
u
s
c
l
e
 
m
a
s
s
C
h
a
n
g
e
s
 
i
n
 
G
F
R
H
y
p
e
r
t
h
y
r
o
i
d
i
s
m
,
 
C
o
r
t
i
c
o
s
t
e
r
o
i
d
s
I
C
U
 
p
a
t
i
e
n
t
s
,
 
1
 
d
a
y
 
p
r
i
o
r
 
t
o
 
c
l
i
n
i
c
a
l
 
A
K
I
>
 
5
0
%
 
r
i
s
e
 
f
r
o
m
 
b
a
s
e
l
i
n
e
 
s
e
r
u
m
 
c
r
e
a
t
i
n
i
n
e
>
 
5
0
 
%
 
r
i
s
e
0
.
8
2
0
.
9
5
0
.
9
7
M
i
s
h
r
a
 
e
t
 
a
l
.
 
N
 
=
 
7
1
 
[
3
2
]
U
r
i
n
e
 
N
G
A
L
2
5
 
K
D
a
 
p
r
o
t
e
i
n
 
b
o
u
n
d
 
t
o
 
g
e
l
a
t
i
n
a
s
e
 
f
r
o
m
 
n
e
u
t
r
o
p
h
i
l
s
I
s
c
h
e
m
i
a
N
e
p
h
r
o
t
o
x
i
n
s
U
T
I
C
K
D
S
y
s
t
e
m
i
c
 
s
e
p
s
i
s
C
a
r
d
i
a
c
 
s
u
r
g
e
r
y
C
h
i
l
d
r
e
n
2
 
h
 
p
o
s
t
-
s
u
r
g
e
r
y
5
0
 
μ
g
/
l
 
>
5
0
 
%
 
r
i
s
e
1
.
0
0
.
9
8
0
.
9
9
P
a
r
i
k
h
 
e
t
 
a
l
.
 
N
 
=
 
7
1
 
[
3
4
]
U
r
i
n
e
 
I
L
-
1
8
P
r
o
-
i
n
fl
 
a
m
m
a
t
o
r
y
 
c
y
t
o
k
i
n
e
 
r
e
g
u
l
a
t
i
o
n
 
o
f
 
T
-
h
e
l
p
e
r
 
c
e
l
l
s
.
 
I
n
d
u
c
e
d
 
a
n
d
 
c
l
e
a
v
e
d
 
i
n
 
p
r
o
x
i
m
a
l
 
t
u
b
u
l
e
 
a
f
t
e
r
 
A
K
I
I
s
c
h
e
m
i
a
(
N
o
t
 
r
a
i
s
e
d
 
i
n
 
C
K
D
,
 
U
T
I
 
o
r
 
p
r
e
-
r
e
n
a
l
 
A
K
I
)
C
a
r
d
i
a
c
 
s
u
r
g
e
r
y
1
2
 
h
 
p
o
s
t
-
s
u
r
g
e
r
y
5
0
 
p
g
/
m
l
>
 
5
0
 
%
 
r
i
s
e
0
.
5
0
.
9
4
0
.
7
3
H
a
n
 
e
t
 
a
l
.
 
N
 
=
 
4
0
 
[
3
5
]
U
r
i
n
e
 
K
I
M
-
1
T
y
p
e
 
1
 
t
r
a
n
s
m
e
m
b
r
a
n
e
 
p
r
o
t
e
i
n
 
n
o
t
 
d
e
t
e
c
t
e
d
 
i
n
 
n
o
r
m
a
l
 
k
i
d
n
e
y
.
 
H
i
g
h
l
y
 
e
x
p
r
e
s
s
e
d
 
i
n
 
p
r
o
x
i
m
a
l
 
t
u
b
u
l
e
 
a
f
t
e
r
 
A
K
I
I
s
c
h
e
m
i
a
N
e
p
h
r
o
t
o
x
i
n
s
(
N
o
t
 
r
a
i
s
e
d
 
i
n
 
C
K
D
,
 
U
T
I
 
o
r
 
p
r
e
-
r
e
n
a
l
 
A
K
I
)
C
a
r
d
i
a
c
 
s
u
r
g
e
r
y
1
2
 
h
 
p
o
s
t
-
s
u
r
g
e
r
y
7
 
n
g
/
m
g
/
 
s
e
r
u
m
 
c
r
e
a
t
i
n
i
n
e
>
 
5
0
 
%
 
r
i
s
e
0
.
7
4
0
.
9
C
K
D
:
 
c
h
r
o
n
i
c
 
k
i
d
n
e
y
 
d
i
s
e
a
s
e
;
 
A
K
I
;
 
a
c
u
t
e
 
k
i
d
n
e
y
 
i
n
j
u
r
y
;
 
U
T
I
:
 
u
r
i
n
a
r
y
 
t
r
a
c
t
 
i
n
f
e
c
t
i
o
n
;
 
N
G
A
L
:
 
n
e
u
t
r
o
p
h
i
l
 
g
e
l
a
t
i
n
a
s
e
 
l
i
p
o
c
a
l
i
n
;
 
I
L
:
 
i
n
t
e
r
l
e
u
k
i
n
;
 
K
I
M
:
 
k
i
d
n
e
y
 
i
n
j
u
r
y
 
m
o
l
e
c
u
l
e
;
 
G
F
R
:
g
l
o
m
e
r
u
l
a
r
 
fi
 
l
t
r
a
t
i
o
n
 
r
a
t
e
;
 
I
C
U
:
 
i
n
t
e
n
s
i
v
e
 
c
a
r
e
 
u
n
i
t
;
 
A
U
C
:
 
a
r
e
a
 
u
n
d
e
r
 
t
h
e
 
c
u
r
v
e
;
 
N
R
:
 
n
o
t
 
r
e
p
o
r
t
e
d
Slack et al. Critical Care 2010, 14:214 
http://ccforum.com/content/14/2/214
Page 6 of 10already demonstrated the usefulness of NGAL post-
ortho  topic liver transplantation to predict AKI [37]. 
Whether this will translate to improved kidney injury 
outcomes remains to be demonstrated, but it is intuitive 
to believe that an earlier diagnosis would be associated 
with improved outcomes, much like troponin in patients 
with acute coronary syndromes.
Kidney Disease Outcome Quality Initiative criteria 
for staging chronic kidney disease
Th  e  deﬁ  nition and classiﬁ  cation of chronic kidney disease 
was established in 2002 by the Kidney Disease Outcome 
Quality Initiative (KDOQI) group in the USA [38]. Th  ere 
were numerous factors prompting the group to establish 
clarity for the deﬁ  nition of chronic renal failure, which 
was already an extensive health care burden. With up to 
100,000 new patient cases per year reaching end-stage 
renal disease, something had to done to try and detect 
kidney disease earlier.
Th  e Cockcroft-Gault equation [39] has been widely 
used to detect renal dysfunction, adjust drug dosing for 
drugs excreted by the kidneys, and assess the eﬀ  ective-
ness of treatments for progressive kidney disease. It has 
also been used to evaluate patient’s health insurance 
claims and assign them points, which would prioritize 
them on the waiting list for a kidney transplant, similar to 
the way in which the model for end-stage liver disease 
(MELD) is now used for liver transplantation. However, 
there is established evidence that the degree of chronic 
kidney disease and not just end-stage renal disease is an 
important risk factor for cardiovascular disease and AKI 
[40]. Moreover, new treatments, in particular angiotensin 
converting enzyme (ACE) inhibitors, have been shown to 
slow the progression of chronic kidney disease by 
reducing the damaging eﬀ   ects of the proteinuria and 
raised intra-glomerular pressure encountered with 
hyper tension  [41].
It was recognized that the Cockcroft-Gault equation 
relied on the serum creatinine concentration, which is 
notably aﬀ  ected by age, gender, and ethnicity. Th  e  MDRD 
study in 1999 [42] was undertaken to assess patients with 
established chronic kidney disease and the eﬀ  ect  that 
dietary protein restriction and strict blood pressure 
control had on preventing the progression of chronic 
kidney disease. In this study, a baseline period was used 
to collect demographic data, and to perform timed urine 
creatinine clearance and I-Iothalamate radionucleotide 
GFR measurement on the enrolled patients. Th  e  investi-
gators formulated seven equations using a number of 
combinations including demographic, serum, and urine 
variables, and incorporating gender, age, ethnicity and 
serum creatinine. In version 7 of the equation, the 
additional serum variables of albumin and urea were 
used in place of the urine variable. Th  is equation 
provided a validated estimated measure of GFR in 
patients with chronic kidney disease and from this the 
staging classiﬁ   cation was developed. Importance was 
leveled at establishing a staging system, because adverse 
outcomes in chronic kidney disease are linked to the 
degree of chronic kidney disease and future loss of kidney 
function. Additionally, chronic kidney disease was 
understood to be a progressive disease and consequently 
the staging classiﬁ   cation could be adapted to give 
emphasis to treatment goals to slow progression. Th  e 
term ‘chronic renal failure’ was redeﬁ   ned in a similar 
fashion to ‘acute renal failure’ and newly termed ‘chronic 
kidney disease’. It was then possible to classify chronic 
kidney disease into ﬁ   ve stages for patients with renal 
disease and the old classiﬁ  cation of mild, moderate, or 
severe chronic renal failure was abandoned [42].
Th  ese ﬁ   ve stages have been under review given the 
epidemiological data demonstrating a signiﬁ  cant 
diﬀ  erence in patient numbers in chronic kidney disease 
stages 3 and 4 [43]. Th  is  diﬀ  erence has been attributed to 
the signiﬁ   cant increase in cardiovascular associated 
mortality in late chronic kidney disease stage 3 (estimated 
GFR 30–45  ml/min/1.73  m2). Consequently chronic 
kidney disease stage 3 is now subdivided into 3A 
(estimated GFR 59–45  ml/min/1.73  m2) and 3B 
(estimated GFR 44–30 ml/min/1.73 m2) (Table 3).
Th  ere are problems with this staging system, which 
relate to the original study population and its application 
to the wider community. An MDRD equation calculation 
for an estimated GFR above 60 ml/min/1.73 m2 has been 
shown to be inaccurate, underestimating GFR in patients 
with normal kidney function [43]. Th  e original study 
population had a mean GFR of 40 ml/min/1.73 m2 and 
included only a few Asian, elderly, and diabetic patients. 
Th  ere are debates about the critical level of estimated 
GFR for chronic kidney disease in terms of cardiovascular 
risk, currently deemed to be around 60 ml/min/1.73 m2, 
and the relation of this level to the age and ethnicity of 
the patient, and the chronicity of the condition. All have a 
bearing on the implications of labeling patients as having 
chronic kidney disease and the treatments, if necessary, 
to address cardiovascular risk and disease progression 
[26, 44].
Table 3. Kidney Disease Outcome Quality Initiative 
(KDOQI) staging criteria for chronic kidney disease [38]
  Stage  Estimated GFR (ml/min/1.73 m2)
 1  >90
 2  89–60
 3A  59–45
 3B  44–30
 4  29–15
 5  <15
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with chronic liver disease
Th   e reliance on serum creatinine concentration is pivotal 
to the problems with estimated GFR and the gulf between 
the original MDRD study population and patients with 
chronic liver disease. Th  is has been highlighted by a 
meta-analysis that reviewed creatinine clearance and 
estimated GFR and demonstrated a mean overestimation 
of 18.7  ml/min/1.73  m2 [45]. Timed urine creatinine 
clearance also performs poorly, signiﬁ  cantly overestimating 
GFR in patients with chronic liver disease, particularly at 
the lower range of GFR measurements [46]. So why use 
estimated GFR if it performs so poorly? Despite its draw-
backs, it is the most cost-eﬀ  ective method of assessing 
kidney function in the chronic setting and provides 
greater clarity on the extent of disease if one considers 
the overestimation and uses the extended version, which 
incorporates albumin and urea. Serial measures tend to 
provide greater information than measures in isolation.
Future directions
Patients with chronic liver disease and chronic kidney 
disease warrant better evaluation of residual kidney 
function than is currently oﬀ  ered. Cystatin C has been 
shown to be a better marker of GFR in patients with 
chronic liver disease both before and in the immediate 
period after transplantation [47, 48]. Equations have been 
developed to give better accuracy to the estimation of 
GFR using measured cystatin C concentration [48]. 
However, these equations have been evaluated in small 
study populations using diﬀ  erent gold standard measures 
of GFR compared to the creatinine based equations. 
Cystatin C equations have, though, been shown to 
perform better, with greater accuracy in predicting GFR, 
in cirrhotic and post-transplant patients using either the 
Hoek or Larsson equations [47, 48].
uNGAL has also been shown to be signiﬁ  cantly elevated 
in proteinuric patients with membranous nephro  pathy or 
membranoproliferative glomerulo  nephritis with chronic 
kidney disease when compared to a control group with 
normal kidney function and no proteinuria [30]. sNGAL 
has been shown to be signiﬁ  cantly elevated in patients 
with chronic kidney disease or kidney transplant 
compared to controls [37]. It also appears to increase 
with chronic kidney disease stage and severity suggesting 
a role in tracking progression of chronic kidney disease 
[49]. However, increased sNGAL in the setting of chronic 
kidney disease is poorly understood; the suggested 
hypothesis links proteinuria and the apoptotic eﬀ  ect this 
has on proximal tubular cells. Further evaluation is 
required, but these biomarkers have shown promise as 
markers of chronic kidney disease progression.
Ultimately, patients with chronic liver disease and 
chronic kidney disease need residual kidney function to be 
evaluated using gold standard measures of GFR, probably 
at 3–6 monthly intervals. Th   e evaluation of cystatin C and 
serum NGAL in the interim period to monitor progression 
and perhaps detect acute changes could lead to improved 
outcomes for this group of patients.
Orthotopic liver transplantation
OLT oﬀ  ers the best long-term outcome for patients with 
advanced liver disease. Th  e method for allocating liver 
grafts to patients with advanced liver disease relies on 
scoring systems, like MELD, which helps to predict 
survival without transplantation. Th   e MELD score 
incorporates serum creatinine and this carries a high 
integer weighting which may have a signiﬁ  cant impact on 
the composite score. Consequently, there are two 
signiﬁ   cant problems associated with MELD. First, the 
prognostication of chronic liver disease itself is somewhat 
blurred by the emphasis apportioned to kidney 
dysfunction. Second, the reliance on serum creatinine 
potentially underestimates prognosis with respect to 
renal outcomes and overestimates true prognosis with 
respect to liver outcomes. To address this imbalance, 
MELD should perhaps incorporate a measure of GFR, 
either by using a gold standard measure of GFR or 
cystatin C, to more accurately represent residual kidney 
function. In recognition of these problems, MELD has 
been adapted to form the UKELD score, which 
incorporates the serum sodium concentration, with 
downward adjustment of the integer weighting for serum 
creatinine [51]. Consequently, in the UK population, 
UKELD is a better predictor of survival following listing 
for liver transplantation [50].
Th  e incidence of chronic kidney disease among liver 
recipients is high, around 27%, and up to 10% reach end-
stage, requiring renal replacement therapy within 10 
years [51]. Th  ere are a number of independent risk 
factors in the pre-transplant period that are associated 
with chronic kidney disease post-transplantation. Th  ese 
include chronic kidney disease stage, age, gender, 
ethnicity, and the presence of hypertension, diabetes and 
hepatitis C prior to transplantation [52]. Importantly, 
chronic kidney disease post-liver transplantation is 
associated with a four-fold increase in mortality [53]. 
Strategies have focused on tailoring immunosuppression 
regimens to improve long-term renal outcome, in 
particular, reducing the nephrotoxic calcineurin inhibitor 
burden, which is often possible due to the immuno-
tolerant properties of the liver. Th  e ReSpECT study 
compared standard tacrolimus dosing and steroids; low-
dose tacrolimus plus steroids; and delayed introduction 
and low-dose tacrolimus plus steroids plus myco-
phenolate moeﬁ  til. Th  e authors demonstrated reduced 
nephrotoxicity in the delayed, low dose tacrolimus group 
[54]. Daclizumab, a monoclonal antibody, was used to 
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period before the introduction of tacrolimus. Th  e study 
had a few limitations, however, namely the use of 
estimated GFR calculated with the Cockcroft- Gault 
formula, and the fact that a signiﬁ  cant number of patients 
were withdrawn from the high dose group. However, it 
importantly demonstrated that the tailoring of an 
immunosuppressive regimen can have a signiﬁ  cant 
impact on nephrotoxicity without detrimental eﬀ  ects on 
graft function or patient survival [54].
Th  ere has also been an increasing trend toward 
combined liver-kidney transplant if patients have AKI or 
chronic kidney disease prior to transplantation. However, 
appropriate allocation of these organs to patients that are 
most suitable for either OLT alone or combined liver-
kidney transplant has created a major dilemma as no 
single reliable factor has been shown to be predictive of 
renal recovery or progression of chronic kidney disease 
after successful OLT.
Pre-emptive kidney transplantation for patients with 
isolated kidney disease is considered if dialysis is 
predicted to start within 6 months, which is typically 
associated with a GFR less than 15 ml/min. Combined 
liver-kidney transplant is currently indicated for those 
with combined kidney and liver disease on hemodialysis 
with viral, polycystic, or primary oxaluria as etiologies. In 
this scenario, there is a drive to transplant these patients 
earlier when their liver disease is not so advanced, e.g., 
Child Pugh score A or B, because of worse outcomes 
associated with Child Pugh C cirrhosis. Extensive poly-
cystic liver and kidney disease where the mass of cysts 
exceeds 20 kg causing malnutrition and cachexia is seen 
as an indication for transplantation, even though liver 
synthetic function is often well preserved. Primary 
oxaluria type 1 is an enzymatic defect resulting in renal 
calculi and extensive extrarenal oxalate deposits. 
Combined liver-kidney transplant is recommended early 
in the course of this disease to prevent extra renal 
manifes  tations, in a similar way to familial amyloidosis 
polyneuropathy [55].
End-stage liver and kidney disease is a recognized 
indication for combined liver-kidney transplant and was 
ﬁ   rst performed in 1983. Retrospective studies have, 
however, evaluated factors that may help predict the 
reversibility of kidney dysfunction in patients with end-
stage liver disease. Th  ere is some evidence that chronic 
kidney disease (deﬁ  ned as renal dysfunction for more than 
12 weeks), pre-transplant serum creatinine > 160 umol/l, 
and diabetes, are predictors of poor post-transplant 
kidney function with estimated GFR of less than 20 ml/
min/1.73 m2 [52]. Th  ere is a paucity of research in this 
ﬁ  eld. Th   e implementation and use of improved measures 
of residual kidney function and the incorporation of 
these into MELD would help to more precisely prioritize 
patients and ensure organ allocation is appropriate for 
liver, kidney, and combined transplant procedures.
Conclusion
Chronic liver disease is associated with primary and 
secondary kidney disease and impacts markedly on 
survival. Th  e evaluation of kidney function and injury 
relies on the measurement of the concentration of serum 
creatinine, which is aﬀ  ected by the degree of liver disease 
and the analytical method employed. Th   e integral role of 
creatinine concentration in the diﬀ  erent classiﬁ  cations of 
AKI, chronic kidney disease and the survival predictive 
score, MELD, for chronic liver disease, confers large 
inaccuracies across this population, but currently oﬀ  ers 
the most cost-eﬀ  ective measure available. Hepatologists 
should perhaps use exogenous measures of kidney 
function and biomarkers, like cystatin C and the cystatin 
C-based equation for estimated GFR, more frequently, as 
these have been shown to be superior to creatinine. 
Improved assessment of the degree of residual kidney 
function may assist clinical decisions regarding risk of 
AKI, drug therapy in chronic liver disease, the tailoring of 
post-liver transplant immunosuppression regimens, and 
the allocation of organs for combined liver and kidney 
transplantation. Kidney injury biomarkers need further 
evaluation in the chronic liver disease population, but 
they seem likely to continue to perform well. Earlier 
diagnosis and implementation of currently established 
beneﬁ   cial therapies seems to be pivotal in potentially 
reducing the severity of kidney injury and increasing 
survival outcomes; whether this will be realized remains 
to be seen.
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